Urol. praxi, 2014; 15(2): 72-76
Bladder carcinoma from the perspective of a clinical oncologist
- Onkologicko-chirurgické oddělení FN u sv. Anny, Brno
The treatment of bladder carcinoma requires a multidisciplinary approach. The therapeutic strategy for bladder carcinoma is chosen
based on the disease category. Administration of chemotherapy is used not only in noninvasive, but mainly in invasive carcinoma in
neoadjuvant, adjuvant as well as palliative therapies.
Keywords: bladder carcinoma, instillation therapy, neoadjuvant chemotherapy, adjuvant chemotherapy, palliative chemotherapy
Published: April 21, 2014 Show citation
References
- Šlampa P, Petera J, et al. Radiační onkologie, 1. vyd. GalénKarolinum, 2007: 315-323 s.
- Doporučení České urologické společnosti, www.cus.cz.
- Natale RB, Grossman HB, Blumenstein B, et al. SWOG 8710 (INT -0080) Randomized phase III trial of neadjuvant M-VAC + cystectomy versus cystectomy alone in patients with locally advanced bladder cancerProc Am Soc Clin Oncol 2001; 20 (abstr.3): 2a.
- De Mulder PHM, Current status of systemic treatment in locally advanced and metastatic bladder cancerRenal, bladder, prostate and testicular cancer an update, 2001: 281.
- Sternberg CN, Yagoda A, Scher HI, et al. Methotrexate, vinblastine, doxorubicin and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse. Cancer 1989; 64(12): 2448-2458.
Go to original source... - von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatine versus methotrexate, vinblastine, doxorubicin and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000; 18(17): 3068-3077. Go to original source...
Go to PubMed... - Bellmunt J, von der Maase H, Mead GM, et al. Randomized phase III study comparing paclitaxel/cisplatine/gemcitabine (PCG) and gemcitabine/cisplatin (GC) in patients with locally advanced (LA) or metastatic (M) urothelial cancer without prior systemic therapy. American Society of Clinical Oncology Annual Meeting 2007; Chicago, IL. Go to original source...
- Albers P, Park SI, Niegisch G, et al. Randomized phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment (German Association of urological Oncology (AUO) trial AB 20/99) Ann Oncol. 2011; 22(2): 288-294. Go to original source... Go to PubMed...
- Bellmunt J, Theodore C, Demkov T, et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol 2009 Sep 20; 27(27): 4454-4461. Go to original source... Go to PubMed...
- Oosterlinck W, Van der Meijden A, et al. Guidelines EAU pro karcinom močového měchýře (TaT1 - neinvadujícího svalovinu). Urol List 2008; 6(2): 121-131.
- Niegisch G, Lorch A, et al. Neoadjuvant Chemotherapy in Patient with Muscle-invasive Bladder Cancer: Which Patients Benefit? Eur Urol 2013; 64: 355-357. Go to original source... Go to PubMed...